

9th July, 2026

BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Successful closure of US FDA Inspection at Piramal Pharma's manufacturing facility located at Sellersville (USA) facility

Dear Sir / Madam,

Kindly refer to our letter dated 10th May, 2026 regarding US FDA Inspection at Piramal Pharma Limited's manufacturing facility located at Sellersville (USA).

In furtherance to the aforementioned intimation, this is to inform you that US FDA has issued an Establishment Inspection Report (EIR) for the said manufacturing facility, and the inspection has now been successfully closed by the US FDA.

This is for your information and records.

Thank you.

Yours truly,
For **Piramal Pharma Limited**

Maneesh Sharma
Company Secretary and Compliance Officer